- AimedBio has entered into an exclusive global license agreement with U.S.-based Biohaven for the development and
commercialization of AMB302, an FGFR3-targeting ADC.
-
Under the agreement, Biohaven
will lead the Phase 1 clinical trial in the United States.
-
Financial details, including
upfront payments and the total deal size, were not disclosed.
Link to full news: https://bqura.com/posts/284